Source: Annual Congress 2007 - Clinical tuberculosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
J. M. Garcia-Garcia, F. Alvarez-Navascues, M. Garcia-Clemente, J. Allende, J. Ferreiro, M. Martinez-Muñiz, A. Sanchez-Antuña (Aviles, Asturias, Spain). When do we extend the treatment of tuberculosis (TB) more than 6 months?. Eur Respir J 2007; 30: Suppl. 51, 1206

Member's Comments

No comment yet.

Related content which might interest you: One year follow-up of T-SPOT. TB results in treated patients with active tuberculosis Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease Year: 2007 Tolerance to rifampicine (RIF) 4 months vs. isoniazid (INH) 6 months for latent tuberculosis infection (LTBI) Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis Year: 2008 Outcomes of 6-9-12 months’ bedaquiline-containing regimens in MDR/XDR TB after 24 months follow up Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 A comparison of on-site versus remote physician follow up of directly observed preventive treatment (DOPT) for latent tuberculosis infection (LTBI) on completion rates Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology II Year: 2012 Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population Source: Eur Respir J 2005; 26: Suppl. 49, 624s Year: 2005 Treatment outcomes of tuberculosis patients under directly observed therapy (DOT) for three years Source: Eur Respir J 2004; 24: Suppl. 48, 653s Year: 2004 Multidrug-resistant tuberculosis: treatment outcome after 18 months of invidualised therapy Source: Eur Respir J 2001; 18: Suppl. 33, 314s Year: 2001 Systematic review of shorter 2-3 months regimens for treatment of latent tuberculosis Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis Year: 2013 High completion rates with directly observed preventive treatment (DOPT) of latent tuberculosis infection (LTBI) in Ethiopian immigrants (EI) to Israel Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I Year: 2012 Predictors of delayed smear conversion after 2 months of tuberculosis treatment Source: Annual Congress 2012 - Tuberculous and non-tuberculous mycobacterial infections: epidemiology I Year: 2012 What is latent tuberculosis infection (LTBI)? Source: Annual Congress 2009 - Microbial colonisation or latency: a foot in the door to respiratory infections Year: 2009 The role of quantiferon tuberculosis gold test (Q) in diagnosing active tuberculosis (TB) and latent tuberculosis infection (LTI) in children Source: Annual Congress 2008 - New tests and methods to diagnose tuberculosis infection and disease and to monitor treatment Year: 2008 Comparison of two different cohorts of patients for multidrug-resistant tuberculosis treatment evaluation Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB) Year: 2006 Long term plasma rifampicin (R) concentrations in AIDS patients with tuberculosis (TB) under HAART therapy Source: Eur Respir J 2003; 22: Suppl. 45, 40s Year: 2003 Tuberculin skin test (TST) conversions rates, its relationship with interferon gamma release assay and safety and efficacy of 4 months rifampicin therapy (4R) for latent TB infection (LTBI) among nursing students in south India Source: Annual Congress 2010 - Special treatment options in tuberculosis Year: 2010 The efficiency of the treatment of the patients with culture-positive pulmonary tuberculosis (CPPTB) in Gdannsk, Poland in 1995 and 2000 Source: Annual Congress 2005 - Epidemiology and control of tuberculosis and LTBI Year: 2005 Empirical treatment for tuberculosis: survey of cases treated over a period of two years Source: Eur Respir J 2002; 20: Suppl. 38, 566s Year: 2002 High rate of hepatitis due to treatment with pyrazinamide (PYR) and ethambutol (EMB) for latent tuberculosis infection (LTBI) in subjects exposed to MDR-TB Source: Annual Congress 2005 - Management of tuberculosis pulmonary, extrapulmonary peculiarities Year: 2005 TB re-treatment results in relapses, default and failure – cohort study for 7 years Source: Annual Congress 2006 - Clinical epidemiology of tuberculosis Year: 2006 Evaluation of new smear positive tuberculosis patients 5 years after initiation of treatment under a DOTS programme Source: Annual Congress 2010 - Tuberculosis epidemiology Year: 2010